Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
Cost-Effectiveness of Nociscan: Aclarion's Nociscan has been found to save $1,712 per patient and improve surgical success rates by 10% compared to traditional provocative discography for diagnosing chronic low back pain.
Innovative Diagnostic Tool: Nociscan utilizes Magnetic Resonance Spectroscopy and AI algorithms to noninvasively identify painful discs in the lumbar spine, providing critical insights that can enhance treatment strategies for patients suffering from chronic low back pain.
Trade with 70% Backtested Accuracy
Analyst Views on ACONW
No data
About the author
Aclarion Names Dan Isherwood as UK Commercial Director to Enhance Adoption and Expand Market Reach
Aclarion's New Hire: Aclarion, Inc. has appointed Dan Isherwood as UK Commercial Director, marking a significant step in their commercial strategy to drive the adoption of their Nociscan technology for chronic low back pain.
Market Traction in the UK: Nociscan has gained strong traction in the UK, being reimbursed by three of the top four private insurers, which provides access to over 5.2 million covered lives, facilitating easier access for patients.
Nociscan Technology: Nociscan is an innovative SaaS platform that uses Magnetic Resonance Spectroscopy to help physicians differentiate between painful and nonpainful discs in the lumbar spine, potentially improving surgical outcomes.
Global Impact of Chronic Pain: Chronic low back pain affects an estimated 266 million people worldwide, highlighting the importance of Aclarion's technology in addressing this widespread health challenge.
Aclarion Recognized as "Rising Star" at 2025 Digital Health Awards by the Digital Health Hub Foundation at HLTH
Award Recognition: Aclarion, Inc. was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Awards, highlighting its innovative Nociscan solution for chronic low back pain among over 1,800 submissions.
Nociscan Technology: The Nociscan platform utilizes Magnetic Resonance Spectroscopy and AI algorithms to help physicians identify painful versus non-painful discs in the lumbar spine, aiming to improve treatment plans for the estimated 266 million people suffering from chronic low back pain globally.
Aclarion Unveils MR Spectroscopy Application for Detecting Discogenic Pain Biomarkers at Global Neuroscience Conference
Panel Discussion at ISPN Annual Meeting: Aclarion, Inc. participated in the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, focusing on the use of MR Spectroscopy to identify discogenic pain biomarkers, with insights from experts in the field.
Nociscan Technology: Aclarion's Nociscan® is a pioneering SaaS platform that utilizes MR spectroscopy and AI algorithms to help physicians differentiate between painful and non-painful lumbar discs, aiming to improve treatment strategies for chronic low back pain affecting over 266 million people globally.
Aclarion Recognized as a Finalist for the 2025 Digital Health Awards by the Digital Health Hub Foundation at HLTH
Recognition of Aclarion: Aclarion, Inc. has been selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation Awards, highlighting its innovative approach to addressing chronic low back pain through its Nociscan technology.
Nociscan Technology: Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians differentiate between painful and non-painful lumbar discs, utilizing magnetic resonance spectroscopy and proprietary algorithms to provide actionable insights for personalized treatment plans.
Aclarion Showcases Nociscan Technology and Essential Value Drivers at LSI Europe '25
Aclarion's Nociscan Technology: Aclarion, Inc. presented its Nociscan platform at LSI Europe '25, which utilizes MR spectroscopy and augmented intelligence to provide objective insights into chronic low back pain, helping physicians differentiate between painful and non-painful discs.
Clinical Trial and Financial Position: The company is conducting a pivotal 300-patient CLARITY trial to improve surgical outcomes for chronic low back pain, with strong financial backing to support its commercial and clinical goals.
UHealth – University of Miami Welcomes First Participants in Aclarion's Key CLARITY Trial
Enrollment and Study Overview: Aclarion, Inc. has initiated the CLARITY trial at the University of Miami Health System, enrolling its first two patients to evaluate the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain.
Nociscan Technology: Nociscan utilizes MR Spectroscopy and AI to help identify sources of low back pain, aiming to become the gold standard in the field by distinguishing between painful and nonpainful discs in the lumbar spine.
Aclarion Names Dan Isherwood as UK Commercial Director to Enhance Adoption and Expand Market Reach
Aclarion's New Hire: Aclarion, Inc. has appointed Dan Isherwood as UK Commercial Director, marking a significant step in their commercial strategy to drive the adoption of their Nociscan technology for chronic low back pain.
Market Traction in the UK: Nociscan has gained strong traction in the UK, being reimbursed by three of the top four private insurers, which provides access to over 5.2 million covered lives, facilitating easier access for patients.
Nociscan Technology: Nociscan is an innovative SaaS platform that uses Magnetic Resonance Spectroscopy to help physicians differentiate between painful and nonpainful discs in the lumbar spine, potentially improving surgical outcomes.
Global Impact of Chronic Pain: Chronic low back pain affects an estimated 266 million people worldwide, highlighting the importance of Aclarion's technology in addressing this widespread health challenge.
Aclarion Recognized as "Rising Star" at 2025 Digital Health Awards by the Digital Health Hub Foundation at HLTH
Award Recognition: Aclarion, Inc. was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Awards, highlighting its innovative Nociscan solution for chronic low back pain among over 1,800 submissions.
Nociscan Technology: The Nociscan platform utilizes Magnetic Resonance Spectroscopy and AI algorithms to help physicians identify painful versus non-painful discs in the lumbar spine, aiming to improve treatment plans for the estimated 266 million people suffering from chronic low back pain globally.
Aclarion Unveils MR Spectroscopy Application for Detecting Discogenic Pain Biomarkers at Global Neuroscience Conference
Panel Discussion at ISPN Annual Meeting: Aclarion, Inc. participated in the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, focusing on the use of MR Spectroscopy to identify discogenic pain biomarkers, with insights from experts in the field.
Nociscan Technology: Aclarion's Nociscan® is a pioneering SaaS platform that utilizes MR spectroscopy and AI algorithms to help physicians differentiate between painful and non-painful lumbar discs, aiming to improve treatment strategies for chronic low back pain affecting over 266 million people globally.
Aclarion Recognized as a Finalist for the 2025 Digital Health Awards by the Digital Health Hub Foundation at HLTH
Recognition of Aclarion: Aclarion, Inc. has been selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation Awards, highlighting its innovative approach to addressing chronic low back pain through its Nociscan technology.
Nociscan Technology: Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians differentiate between painful and non-painful lumbar discs, utilizing magnetic resonance spectroscopy and proprietary algorithms to provide actionable insights for personalized treatment plans.
Aclarion Showcases Nociscan Technology and Essential Value Drivers at LSI Europe '25
Aclarion's Nociscan Technology: Aclarion, Inc. presented its Nociscan platform at LSI Europe '25, which utilizes MR spectroscopy and augmented intelligence to provide objective insights into chronic low back pain, helping physicians differentiate between painful and non-painful discs.
Clinical Trial and Financial Position: The company is conducting a pivotal 300-patient CLARITY trial to improve surgical outcomes for chronic low back pain, with strong financial backing to support its commercial and clinical goals.
UHealth – University of Miami Welcomes First Participants in Aclarion's Key CLARITY Trial
Enrollment and Study Overview: Aclarion, Inc. has initiated the CLARITY trial at the University of Miami Health System, enrolling its first two patients to evaluate the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain.
Nociscan Technology: Nociscan utilizes MR Spectroscopy and AI to help identify sources of low back pain, aiming to become the gold standard in the field by distinguishing between painful and nonpainful discs in the lumbar spine.
